<p>Aurobindo Pharma Ltd said on Thursday it would make and sell US-based COVAXX's Covid-19 vaccine candidate for supply in India and to the United Nations Children's Fund (UNICEF) under a licensing deal.</p>.<p>The Indian drugmaker also has non-exclusive rights to sell the shot — which is currently undergoing an early-stage trial — in certain other emerging markets, the Hyderabad-based company said in an exchange filing.</p>.<p>COVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the United States.</p>.<p>The companies said the shot uses normal refrigeration as opposed to the freezing temperatures required for some vaccines, seen as beneficial for developing countries.</p>.<p>Shares of Aurobindo Pharma rose as much as 2.3% and were trading up 1.4% as of 0933 IST in an upbeat Mumbai market.</p>.<p>Aurobindo said it could currently produce 220 million doses, but is ramping up its facilities to reach a capacity of nearly 480 million by June 2021.</p>.<p>Its licensing deal comes as Covid-19 infections in India continue to rise after crossing 10 million last week. It's the second worst-hit nation by the pandemic after the United States.</p>.<p><em>Reuters</em> reported on Tuesday that the country is likely to approve Oxford/AstraZeneca's coronavirus vaccine for emergency use by next week.</p>.<p>India, the world's biggest vaccine producing country, is also considering emergency use authorisation applications for vaccines made by Pfizer and local company Bharat Biotech.</p>.<p>Last month, COVAXX said it had received purchase commitments totaling $2.8 billion to deliver more than 140 million doses of its potential Covid-19 vaccine to developing countries, including Brazil, Peru and Ecuador.</p>
<p>Aurobindo Pharma Ltd said on Thursday it would make and sell US-based COVAXX's Covid-19 vaccine candidate for supply in India and to the United Nations Children's Fund (UNICEF) under a licensing deal.</p>.<p>The Indian drugmaker also has non-exclusive rights to sell the shot — which is currently undergoing an early-stage trial — in certain other emerging markets, the Hyderabad-based company said in an exchange filing.</p>.<p>COVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the United States.</p>.<p>The companies said the shot uses normal refrigeration as opposed to the freezing temperatures required for some vaccines, seen as beneficial for developing countries.</p>.<p>Shares of Aurobindo Pharma rose as much as 2.3% and were trading up 1.4% as of 0933 IST in an upbeat Mumbai market.</p>.<p>Aurobindo said it could currently produce 220 million doses, but is ramping up its facilities to reach a capacity of nearly 480 million by June 2021.</p>.<p>Its licensing deal comes as Covid-19 infections in India continue to rise after crossing 10 million last week. It's the second worst-hit nation by the pandemic after the United States.</p>.<p><em>Reuters</em> reported on Tuesday that the country is likely to approve Oxford/AstraZeneca's coronavirus vaccine for emergency use by next week.</p>.<p>India, the world's biggest vaccine producing country, is also considering emergency use authorisation applications for vaccines made by Pfizer and local company Bharat Biotech.</p>.<p>Last month, COVAXX said it had received purchase commitments totaling $2.8 billion to deliver more than 140 million doses of its potential Covid-19 vaccine to developing countries, including Brazil, Peru and Ecuador.</p>